Host-dependent editing of SARS-CoV-2 in COVID-19 patients

Josep Gregori a,b,c, Maria Francesca Cortese d,e, Maria Piñana d,f, Carolina Campos a,b, Damir Garcia-Cehic a,b,c, Cristina Andrés e, Josep Francesc Abril c, Maria Gema Codina a,b, Ariadna Rando g, Juliana Esperalba o, Elena Sulleiro o, Joan Joseph o, Narcís Saubir o, Sergi Colomer-Castell o, Mari Carmen Martin e, Carla Castillo e, Juan Ignacio Esteban o, Tomas Pumarola o,h, Francisco Rodriguez-Frias a,b,d,h, Andrés Antón o,h and Josep Quer o, b

CONTACT Josep Quer josep.quer@vhir.org, josep.quer@ciberehd.org Virus Translational Research Unit, Liver Diseases, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain; Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBERehd), Instituto de Salud Carlos III, Madrid, Spain; Roche Diagnostics SL, Barcelona, Spain; Biochemistry and Microbiology Departments, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain; Respiratory Viruses Unit, Microbiology Department, Vall d’Hebron Institut de Recerca (VHIR), Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain; Computational Genomics Lab, Genetics, Microbiology and Statistics Department, Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain; Microbiology Department, Vall d’Hebron Hospital Universitari, Vall d’Hebron Barcelona Hospital Campus, Barcelona, Spain; Universitat Autònoma de Barcelona, Bellaterra, Spain

ABSTRACT
A common trait among RNA viruses is their high capability to acquire genetic variability due to viral and host mechanisms. Next-generation sequencing (NGS) analysis enables the deep study of the viral quasispecies in samples from infected individuals. In this study, the viral quasispecies complexity and single nucleotide polymorphisms of the SARS-CoV-2 spike gene of coronavirus disease 2019 (COVID-19) patients with mild or severe disease were investigated using next-generation sequencing (Illumina platform). SARS-CoV-2 spike variability was higher in patients with long-lasting infection. Most substitutions found were present at frequencies lower than 1%, and had an A → G or T → C pattern, consistent with variants caused by adenosine deaminase acting on RNA-1 (ADAR1). ADAR1 editing during replication rather than the RNA-dependent RNA polymerase (nsp12) was the predominant mechanism generating SARS-CoV-2 genetic variability. However, the mutations produced are not fixed in the infected human population, suggesting that ADAR1 may have an antiviral role, whereas nsp12-induced mutations occurring in patients with high viremia and persistent infection are the main source of new SARS-CoV-2 variants.

ARTICLE HISTORY Received 6 April 2021; Revised 30 July 2021; Accepted 12 August 2021

KEYWORDS ADAR1; SARS-CoV-2; editing; mutations; quasispecies

Introduction
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causal agent of the acute respiratory syndrome known as coronavirus disease 2019 (COVID-19), replicates by using its own RNA-dependent RNA polymerase (nsp12). SARS-CoV-2 expresses an accessory non-structural protein, nsp14, which has 3′-5′ exonuclease proofreading activity. This feature, which notably limits the acquisition of mutations during replication of the viral genome, is seen in other coronaviruses, such as SARS-CoV and mouse hepatitis virus [1, 2]. Phylogenetic analysis of SARS-CoV-2 consensus sequences has shown only small differences [3], but other sources of variation (insertions, deletions, and recombination events) have been described in several coronaviruses, including SARS-CoV-2 [4–10].

Animal cells have a first-line innate immunity that enables a prompt response to danger signals and pathogens. Interactions between the specialized cellular receptors known as pattern recognition receptors (PRRs) and conserved pathogen-associated molecular patterns (PAMPs) rapidly trigger an innate intracellular antiviral response, usually based on immediate activation of the interferon and NF-kb pathways [11]. Unlike bacteria, viral DNA and RNA have certain features (unusual in the cellular host) that can directly activate specific PRRs. One such PRR is adenosine deaminase acting on RNA1 (ADAR1). ADAR1 directly attacks the virus by deaminating...
adenosine (A) in double-stranded RNA, thereby producing inosine (I) which is misinterpreted as guanosine (G) by the splicing and translation machinery. ADAR1 editing of double-stranded RNA (dsRNA) can be specific (deamination of selected A residues) or almost random. In long dsRNA (>100 bp), this editing can affect 50% of all adenosine residues and cause a hypermutation, as has been reported in some single-stranded RNA viruses during replication and persistent infection [12]. In contrast, short dsRNAs (~20–30 bp) and long dsRNAs with bulges, helixes, hairpins, and loops are edited selectively and only a few adenosines are specifically chosen [13].

RNA editing by ADAR1 has been reported in several viruses [14], where it may contribute to inhibiting viral infection [15]. However, viruses can also take advantage of the variability introduced by cellular mutations in the viral genome and investigate the contribution of the intracellular mutagenic enzyme, ADAR1, to the variability observed.

**Patients and methods**

**Patients**

The study included samples from 18 patients with mild or severe COVID-19 admitted to the emergency room of Hospital Universitari Vall d’Hebron (HUVH), Barcelona (Spain) in March 2020. SARS-CoV-2 infection was diagnosed in the HUVH Microbiology Department using two tests, an in-house PCR assay using the primer/probe set from the CDC 2019-nCoV real-time RT-PCR diagnostic panel (Qiagen, Germany) and the commercial Allplex 2019-nCoV real-time RT-PCR assay (Seegene, Korea). Samples had been collected from the upper respiratory tract (nasopharyngeal/oropharyngeal swabs or nasopharyngeal aspirates). Ten patients had mild symptoms (absence of influenza-like illness or hypoxia and no hospitalization requirement), and 8 patients had severe disease (e.g. pneumonia, hypoxemic respiratory failure, sepsis, cardiomyopathy and arrhythmia, acute kidney dysfunction) and were admitted to the intensive care unit. All patients had a favourable outcome, with resolution of the infection (Table 1). No viral or bacterial co-infections were reported.

The patients included had no comorbidities other than acute respiratory syndrome and were all SARS-CoV-2 monoinfected. All cases included occurred during the first wave of the COVID-19 pandemic, in which treatment of severely ill patients consisted mainly of respiratory maintenance because there had been no previous experience in the management of these patients.

**Methods**

**SARS-CoV-2 sequencing and quality control**

Viruses were inactivated by mixing respiratory specimens with AVL buffer (Qiagen, Hilden, Germany). Viral RNA was extracted using the QIAmp Viral RNA Mini Kit (Qiagen, Hilden, Germany) following the commercial Allplex 2019-nCoV real-time RT-PCR diagnostic panel (Qiagen, Germany) and the commercial Allplex 2019-nCoV real-time RT-PCR assay (Seegene, Korea). Samples had been collected from the upper respiratory tract (nasopharyngeal/oropharyngeal swabs or nasopharyngeal aspirates). Ten patients had mild symptoms (absence of influenza-like illness or hypoxia and no hospitalization requirement), and 8 patients had severe disease (e.g. pneumonia, hypoxemic respiratory failure, sepsis, cardiomyopathy and arrhythmia, acute kidney dysfunction) and were admitted to the intensive care unit. All patients had a favourable outcome, with resolution of the infection (Table 1). No viral or bacterial co-infections were reported.

**Table 1. Clinical and demographic characteristics of COVID-19 patients included in the study.**

| Sample type                      | MILD (n=10) | Severe (n=8) |
|----------------------------------|-------------|--------------|
| Nasopharyngeal aspirate          | 30% (3/10)  | 12.5% (1/8)  |
| Nasopharyngeal/oropharyngeal     | 70% (7/10)  | 87.5% (7/8)  |
| SWAB                             |             |              |
| RT-PCR threshold, Ct median[IQR]*| 23.4 [19.6; 25.5]* | 30.8 [24.2; 32.7]* |
| Sex, % men                       | 30% (3/10)  | 50% (4/8)    |
| Age, years                       | 42 (28; 50)* | 48 (45; 50)* |
| Days in intensive care unit      | Not admitted| 16 (7; 25)*  |

The asterisk (*) indicates the minimum and maximum value of the intervals included in each square bracket. Ct, cycle threshold; IQR, interquartile range.
the manufacturer’s instructions. The complete spike gene was amplified and sequenced into 13 overlapping amplicons, as previously reported by Andres et al. [10].

The RT-PCR amplification and sequencing method has been described [10]. The final library was loaded in a MiSeq Reagent Kit 600V3 cartridge (Illumina, San Diego, CA) and sequenced using the MiSeq platform (Illumina, San Diego, CA), which, in our experience, has the highest resolution power [24, 25]. To obtain high-quality haplotypes, the sequencing reads underwent rigorous quality filters [26]. Reads had to have a minimum of 20 overlapping bases and a maximum of 10% mismatches. Reads that did not fulfill these requirements and those with more than 1% of bases below a Phred score of Q33 (0.9995 accuracy) were excluded.

Reads were demultiplexed by matching primers, allowing a maximum of three mismatches, and the primer sequences at both ends were trimmed off. Identical reads were collapsed to haplotypes, and their corresponding frequencies were expressed as read counts. A fasta file was generated with each pool/primer/strand combination. Reverse haplotypes were reverse-complemented. Haplotypes with more than three gaps were removed. Remaining gaps were repaired based on the most abundant haplotype (master) in the corresponding quasispecies. Haplotypes were selected only if they had both a forward and reverse strand and were present at >0.1% in each strand, providing a robust quality control.

To compensate for the differing coverage of the samples, we established a reference coverage of 70,000 reads and an abundance threshold of 0.15%. Haplotypes present at ≤0.15% were excluded [27].

All computations were done in the R language and platform [28], and in-house scripts were developed using Biostrings [29], Ape [30], ShortRead [31], and ggseqlogo [32].

Quasispecies diversity
Quasispecies diversity indices were calculated based on the characteristics and frequency of all haplotypes observed: number of haplotypes per amplicon, number of polymorphic sites per amplicon, frequency of the dominant haplotype per amplicon, rare haplotype load (RHL) at 0.1% and at 1% per amplicon, Shannon entropy, and mutation frequency [27, 33–36].

Analysis of variants
Minority variants were identified per amplicon, haplotype, and site, and were categorized by type and frequency. Overlapping regions were used as controls to compare variants identified in consecutive amplicons. Potential bias effects due to the primers were controlled by inspecting how the forward and reverse primers of each amplicon were seen in the previous and posterior amplicons, thanks to the amplicon overlapping. No significant conflicts were observed.

Haplotypes in each sample/amplicon were right trimmed to the next amplicon and the spike gene was analyzed haplotype-by-haplotype and site-by-site. A variant was defined as a nucleotide that differed from that of the corresponding dominant haplotype (master sequence).

To study eventual substitution biases, the frequency of a variant per site was computed as the number of haplotypes bearing the variant in the overall study population, without taking into consideration the haplotype frequency in the viral quasispecies of each specific sample/amplicon. The Fisher test was used to contrast biases in the base substitutions from the expected values, and to determine homogeneity vs independence in the distribution of pairs of substitutions.

The above-described analyses were conducted for both the overall study population and for each specific patient. The frequency of each nucleotide, the number of polymorphic sites, and the substitution type (transition or transversion) were determined for each patient.

Characterization of single nucleotide variants (SNVs) by type and frequency
The 3’ end of each amplicon was trimmed to avoid redundancies in the overlaps, and the alignment was used to count the substitutions that occurred. Regardless of the abundance of each haplotype in the quasispecies, the number of SNVs was computed with respect to the quasispecies dominant haplotype in each sample/amplicon.

SNVs were characterized by substitution type and by frequency. Variant abundance was expressed as the percentage of each SNV within the particular quasispecies (per patient and amplicon). To avoid redundancy, SNV percentages in overlapping regions of the amplicon were averaged. In addition, SNVs were characterized as the frequency per abundance bin; that is, the number of SNVs in all the samples (per patient and amplicon) with abundances in the following bins: (0%, 0.2%], (0.2%, 0.5%], (0.5%, 1%], (1%, 2%], (2%, 5%], (5%,10%], and (10%,50%]. The lower bins would be representative of the underlying mechanism causing the substitutions, whereas the higher bins would incorporate the effects of haplotype fitness and selection.

Location of substitutions in the spike gene secondary structure
To study how SNVs could affect the secondary structure of SARS-CoV-2 RNA in the spike region, we used the Wuhan-Hu-1 (MN908927.2) spike gene sequence, with the D614G (A23403G) substitution in the S protein as the backbone, into which each naturally
observed nucleotide substitution was inserted. A minimum free energy (MFE) secondary structure of the spike gene (positive sense for A > G and negative sense for T > C) was generated for each mutant using a loop-based energy model and a dynamic programming algorithm [37], and the RNA folding tools offered by the University of Vienna website resources [38, 39].

**Characterization of fixed mutations worldwide**

To study the type of mutations fixed in SARS-CoV-2 isolates worldwide, we extracted the main SNVs per position from the 353,341 events observed in 48,625 GISAID genomes by Mercatelli and Giorgi [40]. Mutations supported by at least 10 genomes were considered the main SNVs. This computation eliminated prevalence effects due to bias in the geographic origins, resulting from the very different number of genomes from different places. The aim of this computation was not to identify the most prevalent SNVs, but instead, to identify any SNV observed in any genome worldwide and to obtain a count of mutation types.

**Results**

**Spike gene quasispecies diversity**

The SARS-CoV-2 spike gene was extracted, amplified, and sequenced in all patients. In total, 41,326,097 reads passed our quality filter, with a median coverage of 145,391 reads per amplicon (interquartile range [IQR] 115,576–201,833). Coverage of amplicons from patients with severe disease tended to be higher than that of patients with a mild condition (Table 2).

In total, 1536 haplotypes were detected overall with no large differences between the two clinical groups: a median of 4 and 3.5 haplotypes per amplicon was detected in mild and severe cases, respectively (Supplementary Table S1). Most haplotypes per amplicon (1130/1536, 73.6%) were present at ≤0.5% in the respective quasispecies (Supplementary Table S2). In general, each haplotype had a single mutation relative to the master haplotype (Supplementary Table S3).

Analysis of the quasispecies diversity indices in relation to COVID-19 severity showed that diversity (rare haplotype load at 1%, Shannon entropy, and mutation frequency) tended to be higher in severe than in mild cases (Table 2). This trend could be related to the effects of severe disease, to the higher viral load, or to the lengthier disease duration in severe cases. However, some patients with mild disease showed high diversity, whereas some with severe disease showed low diversity (Supplementary Tables S1–S4) with no correlations with viral load, indicating that higher diversity may be driven by the duration of the infection.

**Spike gene variants**

Comparison of spike consensus sequences from all patients with sequences from the Wuhan reference genome (MN908947.3) found that all patients but one (P02) had the A1841G substitution (D614G), which classifies the virus as clade G, and two other patients (P07 and P17) had the G3707T (C1236F) and G3231A (syn.) substitution, respectively.

**Minority variants**

In the total of patients, variant frequency was lower than 2% in most patients with mild disease except for C0890T (s0297L) in P14 and C1467T (Syn) in P15, present at 2.4% and 2.35%, respectively (Supplementary Tables S4 and S5). Variants accounting for >5% of the viral quasispecies were seen in three
patients with severe disease (Figure 1 and Supplementary Table S4). In two of the three, variants were present at >10%: T2875C (Syn) at 21.85% in P08, and G3306T (W1102C) at 11.6% and G1915T (G639C) at 10.8% in P11. The majority of highly frequent mutants (>2% of quasispecies) were found in severe cases (P08, P09, P10, P11, P12, P13, P16, P17) except for the two mutations mentioned above in P14 and P15.

Aggregation of all variants found in all patients by frequency bin (Table 3) and by substitution type yielded 642 polymorphic sites (16.8% of the 3822 bases in the spike gene), with 1090 SNVs. On determination of their abundance in the viral quasispecies, 6 positions had SNVs at ≥5% (Figure 1 and Supplementary Table S4). Of the 1090 SNVs identified, 942 (86.4%) comprised haplotypes present in <0.5% of the quasispecies. Among these, 1052 (96.5%) were transitions, mainly A → G and T → C (908, 83.3%) (Figure 2, Table 3). The SARS-CoV-2 spike gene is AT-rich (62.7%), containing 29.41% A and 33.25% T. However, 83.3% of all substitutions involved A → G and T → C changes (ADAR-type) showing a clear

Figure 1. Single nucleotide variants (SNVs) according to their frequency and position in the spike (S) region. Top panel shows SNVs with frequencies above 1%. Bottom panel shows SNVs below 1%. The spike regions are depicted in different background colours. CP, cytoplasmic domain; FP, fusion peptide; HR, heptad repeat; NTD, N-terminal domain; QS, quasispecies; RBD, receptor-binding domain; SP, signal peptide; TM, transmembrane.
The frequencies are as observed in the corresponding amplicon quasispecies. Transitions (in bold) accounted for 96.44% of observed SNVs. ADAR-type substitutions varied considerably as the abundance of SNVs increased, with values of 172.0 and 14.0, respectively, in the lowest frequency bin (0%, 0.2%), and 0.5 and 0.5, respectively, in the highest bin (1%, 2%) (Table 4). Only 6 SNVs were present at a frequency of >5% (Figure 1, panel A, Supplementary Table S4). The percentage of most SNVs was very low (<1%) (Figure 1, panel B). The fact that the ADAR-type to non-ADAR-type ratio was significantly higher in the lowest bins suggests that ADAR1 was the cause of those substitutions, with hypermutation effects, whereas the higher bins would incorporate the effects of haplotype fitness and selection (Table 4, Supplementary Figures S1 and S2).

Analysis of the mutations in relation to their position in the codon showed that the A → G and T → C transitions were randomly distributed and not restricted to specific positions (Figure 2). A significant overrepresentation of (A → G)/A relative to (G → A)/G, and of (T → C)/T relative to (C → T)/C, both overall and in each codon position, was confirmed by Fisher tests (Supplementary Table S6). The homogeneity of (A → G)/A substitutions with respect to (T → C)/T could not be rejected by Fisher test, which is consistent with the hypothesis that As are equally-likely edited on both strands (See Supplementary Table S7). Among the transversions, there was also a significant overrepresentation of (G → T)/G relative to (T → G)/T.

The analysis was completed by computing the following values for each patient: the number of bases in the respective consensus sequence, the number of polymorphic sites, the number of polyclone sites with A → G transitions, the number of polyclone sites with T → C transitions, and the corresponding fractions with respect to the total of sites, the total of A sites, and the total of T sites (Supplementary Table S8). Median values per patient were, respectively, 1124 A, 723 C, 704 G, 1271 T, 37 polymorphic sites (0.97%), 10 A → G (0.89% of A), and 12 T → C (0.94% of T). Overall there were 1,090 SNVs, 441 (40.5%) A → G transitions, and 467 (40.5%) T → C transitions.

On analysis of the number of substitutions in relation to their sites in the alignment of all 18 patients (Supplementary Table S9), we found 441 SNVs with A → G in any of the 230 sites with this type of substitution, and 467 SNVs with T → C in any of the 254 sites with this type of substitution. Conversely, there were 45 SNVs with G → A in any of the 41 sites with this type of substitution, and 99 SNVs with T → C in any of the 88 sites with this type of substitution. All the transversions observed were unique. In fact, most SNVs involved a single haplotype (Supplementary Table S3).

**Concurrent SNVs**

Analysis of the quasispecies to detect SNVs common to more than one patient found that some variants were present in several patients, including one observed in 11. The mutations common to various patients showed no predilection for any specific region of the spike. The A2194G mutation was detected in 11/18 patients at a minimal abundance of 0.18% and a maximum of 0.26% (Table 5). All concurrent mutations were present at <1.0% (median [IQR] = 0.21% [0.19; 0.245]). Given the low abundance of these concurrent variants along with the very high abundance of the dominant haplotypes (>90%), we can assume that the former were generated independently in each patient during viral replication (Table 5). Moreover, all master sequences had abundances well above 50%, with most of them above 90%; hence, amplicon master sequences were equivalent to the amplicon quasispecies consensus sequences. Because of the high abundance of dominant haplotypes, we suggest that each patient was infected by a single haplotype (bottlenecked effect), and that all
the variants observed had been generated independently within each patient.

The level of concurrency may be better understood if we consider that overall there were 441 \( A \rightarrow G \) substitutions in different haplotypes from the 18 patients, 436 when SNV duplicates in the same patient were removed, corresponding to 230 unique sites, with a ratio of 436/230 = 1.9. Furthermore, there were 467 \( T \rightarrow C \) substitutions in different haplotypes, 460 when duplicates in the same patient were removed, corresponding to 254 unique sites, with a ratio of 460/254 = 1.8.

**Substitution context in the spike gene secondary structure**

In all 18 samples, \( A \rightarrow G \) substitutions were studied to determine whether they were affected by neighbouring nucleotides; no specific pattern was detected at either the 5’ base (16.7% A, 6.0% T, 49.3% G, 28.0% C) or the 3’ base (6.4% A, 7.3% T, 36.0% G, 50.2% C). However, analysis of sites with recurrent mutations found in 5 or more patients showed a more specific pattern at the 5’ base (5.6% C, 94.4% G) and 3’ base (69.4% C, 30.6% G) (Figure 3).

Analysis of the substitution context of the RNA secondary structure only in SNVs common to at least 8 patients showed that the \( A \rightarrow G \) transition in two substitutions (A1988G and A3785G) took place in the helix, one in the hairpin (A2194G), and one in a multibranch loop (A2324G) (Figure 4, panel A-D). In contrast, \( T \rightarrow C \) changes occurred mainly in internal hairpins, with the exception of T1389C, which was found in the helix (Figure 4, panels E-H). None of the substitutions significantly changed the RNA secondary structure except for T1683C, which changed the internal loop into a predicted bulge (Supplementary Figure S3).

**Fixed mutations worldwide**

SNVs observed in 48,625 GISAID genomes worldwide by Mercatelli and Giorgi (2020) [40] were identified. Among the SNV types, we found that the fixed mutations were mainly C → T and G → T dominating (Supplementary Table S10).

**Table 4.** Ratio of transitions to transversions, ADAR-like substitutions to other substitution types, and synonymous to non-synonymous substitutions as observed by frequency bins.

| Frequency bins | (0,0.2] | (0.2,0.5] | (0.5,1] | (1,2] | (2,5] | (5,10] | (10,50] |
|---------------|---------|---------|---------|-------|-------|-------|-------|
| Tr/Tv         | 172     | 33.2    | 26.0    | 2.70  | 7.00  | Inf   | 0.50  |
| ADAR/other    | 14      | 5.54    | 2.12    | 0.61  | 1.29  | 0.50  | 0.50  |
| Syn/NonSyn    | 0.70    | 0.52    | 0.65    | 0.68  | 0.33  | 2.00  | 0.50  |

These results are obtained from Table 3.
Discussion

Although SARS-CoV-2 RNA replication has a proof-reading control, deletions and mutations have been reported in the spike gene [10]. NGS enables the deep study of the viral quasispecies and identification of mutations that might be selected and affect viral replication or pathogenesis. In this study, we analyzed samples from a group of COVID-19 patients with mild or severe disease by NGS at the start of the pandemic to investigate the complexity and variability of the viral quasispecies in the SARS-CoV-2 spike gene.

The variant analysis showed that all overlapping amplicons in the 18 patients had a prominent, highly abundant haplotype as well as a few haplotypes at low abundance bearing a single variant in most cases. Despite the deep analysis performed, no haplotype present in >0.8% of the quasispecies was found to be common to more than one patient. This finding supports the idea that only the most abundant haplotypes were transmitted person-to-person. Furthermore, it would indicate that there is a low probability that variants would be generated along the transmission chain. Instead, variant dominance would mainly occur in patients with a lengthy period of viremia.

The diversity analysis results suggest that SARS-CoV-2 quasispecies maturity and diversity are mainly driven by the duration of the infection, rather than by clinical severity. We found that SARS-CoV-2 is less diverse than other RNA viruses, such as HCV, HIV, and HBV, and that it makes use of mechanisms of

Table 5. Concurrent SNVs.

| Pos | WT | Var | N  | Min Frq (%) | Max Frq (%) |
|-----|----|-----|----|-------------|-------------|
| 2194| A  | G   | 11 | 0.18        | 0.26        |
| 1389| T  | C   | 10 | 0.18        | 0.23        |
| 2324| A  | G   | 10 | 0.18        | 0.40        |
| 1683| T  | C   | 9  | 0.18        | 0.23        |
| 1988| A  | G   | 9  | 0.18        | 0.29        |
| 512 | T  | C   | 8  | 0.18        | 0.27        |
| 2092| T  | C   | 8  | 0.20        | 0.28        |
| 3705| A  | G   | 8  | 0.18        | 0.63        |
| 1224| A  | G   | 7  | 0.19        | 0.26        |
| 1233| T  | C   | 7  | 0.19        | 0.24        |
| 1616| T  | C   | 7  | 0.18        | 0.32        |
| 2443| A  | G   | 7  | 0.18        | 0.54        |
| 2942| T  | C   | 7  | 0.22        | 0.55        |
| 467 | A  | G   | 6  | 0.18        | 0.34        |
| 885 | T  | C   | 6  | 0.18        | 0.27        |
| 1147| T  | C   | 6  | 0.20        | 0.26        |
| 2479| A  | G   | 6  | 0.20        | 0.26        |
| 2902| T  | C   | 6  | 0.19        | 0.24        |
| 2913| T  | C   | 6  | 0.18        | 0.24        |
| 2963| A  | G   | 6  | 0.18        | 0.29        |
| 3298| A  | G   | 6  | 0.19        | 0.24        |
| 3398| T  | C   | 6  | 0.18        | 0.34        |
| 3452| A  | G   | 6  | 0.18        | 0.28        |
| 3588| T  | C   | 6  | 0.18        | 0.31        |
| 3779| A  | G   | 6  | 0.19        | 0.30        |

Position, wild type base, variant base, number of patients with the substitution, and minimum and maximum frequency among all haplotypes showing the substitution. One SNV was seen in 11 patients, 2 were seen in 10 patients, 2 in 9 patients, 3 in 8 patients, 5 in 7 patients, 11 in 6 patients, as well as 13 in 5 patients and 25 in 4 patients that are not in the Table.

Figure 3. Sequence context of SARS-CoV-2 RNA edited sites. Top left includes all sites with A → G transitions. Top right includes sites with A → G concurrent transitions occurring in 4 or more patients. Bottom left includes all sites with T → C transitions. Bottom right includes sites with T → C concurrent transitions occurring in 4 or more patients.
variability other than its own RNA polymerase. The large coronavirus genome requires a balance between stability and diversity. The proofreading exoribonuclease 3’-5’ activity by nsp14 might have an impact on the high fidelity of replication [1, 41, 42]. However, viruses can exploit other sources of variation such as recombination [4] and acceptance of deletions [4–10] and insertions. In addition, they can use cellular mechanisms of innate immunity, such as ADAR1 editing activity [43]. Previous studies investigating the distribution of SARS-CoV-2 mutations [40, 44] are based on consensus sequences downloaded from the GISAID repository database [45, 46]; hence, viral genome subpopulations within the quasispecies of individual patients cannot be analyzed. Here we found that 86.9% of the variants observed using very deep sequencing (>70,000 reads) were present at <0.5%; hence, they can be considered rare variants. These rare variants appeared at the onset of nucleotide edition, prior to any fitness or fixation effects. Rare viral haplotypes may be more representative of the underlying mechanism causing the substitutions, whereas mutants observed at higher rates additionally represent the selected haplotypes with the highest fitness [47]. Accordingly, rare variants will mainly be transient because of their low abundance, low fitness value, or limited time to replicate and reach a significant load, unless a selective pressure (e.g. treatment with convalescent sera or antiviral monotherapy) occurs in patients with lengthy persistence of SARS-CoV-2 infection, such as immunocompromised individuals. In this situation, immune escape or resistant mutants may arise and be selected. This may have been the case of the British (VOC 202012/01), Brazilian (P.1 from B.1.1.28), Japanese (B.1.1.248), and South African (501Y.V2) variants, all sharing the N501Y mutation in the receptor-binding domain of the spike protein. Transmission of minority variants could, however, also occur in patients with lengthy infection and a high viral load, where there would be time enough for the virus to replicate and generate a highly fit variant, or for a variant to occur by chance after a bottlenecks event [48]. However, in the present study viral load did not correlate with COVID-19 disease severity. Severity has been linked with the patients’ demographic data, such as age and sex, and particularly with pre-existing comorbidities such as hypertension, diabetes, cardiovascular disease, chronic lung disease, and cancer, which have been associated with greater severity and a higher fatality rate. Furthermore, COVID-19 contributes to cardiovascular complications, including acute myocardial injury as a result of acute coronary syndrome, myocarditis, stress cardiomyopathy, arrhythmias, cardiogenic shock, and cardiac arrest [49, 50].

Most variants found (96.4%) were transitions, mainly A → G and T → C substitutions (88.1%), consistent with the action of ADAR1 [23]. ADARs edit specific sites or hyper-mutate full viral genes or genomes [51], which leads to mutations that can be selected depending on the dynamic interaction between the virus and host. Several viruses have

**Figure 4.** Location of concurrent substitutions occurring in more than 8 patients. A–D shows substitutions A to G and E–H shows substitutions T to C in the predicted complete spike RNA gene secondary structure of the positive strand in the wild-type (WT) genome.
used this genetic mechanism to generate variability that supports increases in infectivity and evolutionary potential [16–18, 43, 51, 52]. Various SNVs observed in this study were common to more than one patient, although at a low rate (<1%), suggesting that there are preferred nucleotide positions or “hot spots” within the genome where host enzymes such as ADAR1 can act. The probability that a particular point mutation would be found in multiple patients (hypothesis of independence) was almost negligible. Of note, all substitutions present in >3 patients were either A → G or T → C (at nt31 and 32, respectively), suggesting that ADAR1 had a role in generating them. It is important to highlight that the number of true substitutions should be even higher than the values reported in this study because of the very stringent filters used to avoid sequencing artifacts.

To determine whether ADAR1 editing is affected by the 5’ or 3’ neighbours of the substituted nucleotide [36], all A → G and T → C substitutions were analyzed, but no pattern emerged indicating a preferred neighbour on either the 5’ or 3’ end base. However, when only concurrent substitutions common to four or more patients were analyzed, the pattern was surprisingly more specific on both end bases. The 5’ neighbour preference of mutated A → G was G followed by C and A, whereas the 3’ neighbour preference of mutated T → C was C followed by T and G.

Neither the high A → G or T → C bias nor the neighbour preference led to the fixed mutations in the consensus genomes of the GISAID genome [45, 46]. Most recurrent substitutions occurring in four or more of our patients (51 of 63) could not be found in the GISAID genomes analyzed. Nine were found in a single GISAID genome, two were found in two GISAID genomes, and only one in three GISAID genomes. In our view, the most likely explanation for this would be related to the multiple non-specific editions (hypermutations) produced by ADAR. A small fraction of replicating genomes underwent ADAR edition and these sequences were edited several times, reducing the likelihood of replication fitness. That is why most ADAR-type substitutions were detected in genomes present at low rates (genomes with poor fitness) and why very few ADAR1-type substitutions were fixed and detected in consensus genomes (Supplementary Table S10). Thus, a limited ratio of available ADAR molecules to replicating genomes (stoichiometric reason), and a longer time of engagement of each ADAR molecule due to the large genome size, would limit the extension of ADAR1 hypermutation activity to a larger number of genomes, as has been observed in smaller viruses [53, 54]. Our results suggest that most fixed mutations would come from replication errors due to the polymerase, despite the proofreading mechanism.

The ADAR hypermutation hypothesis could be questioned by the fact that most haplotypes carried only a single substitution (Supplementary Table S4). Nonetheless, we should take into account that each amplicon was roughly a 1/13th of the spike gene, which in turn is the most variable region, but only about 10% of the full genome. Hence, if ADAR introduced only 2 substitutions on edited spike genes, it would imply around 20 mutations per genome, most of them non-synonymous (Table 4), which would suffice to impair the edited genomes. Regardless of the mechanism involved, the data suggest that ADAR has an antiviral action on the spike gene, although to a limited extent, as most of the replicating virions remained unaffected.

ADAR1 acts on dsRNA, and editing by this enzyme could occur in either the positive or the negative strand. ADAR editing of the positive strand during viral replication, in which dsRNA is formed, should lead to an A → T transition, whereas ADAR1 editing of the negative strand would result in a T → C transition, once the negative strand has served as the template for a new positive-strand [55]. Because of its considerable length, SARS-CoV-2 RNA has a complex secondary structure, with many double strands forming helices, hairpins, bulges, and loops [37, 38, 56]. Study of the spike secondary RNA structure in substitutions common to more than 8 patients showed that most mutations occurred in hairpins or loops. This suggests that the editing preferably occurred during replication. These results support the concept of multiple ADAR1 editions in a single genome, in either the positive or the negative strand, during RNA replication. Hypermutated genomes could carry deleterious mutations compromising fitness, and in a scenario of low selective pressure, these mutants would have a very low probability of being selected and transmitted. However, ADAR1 editing is a source of variation providing a reservoir of genomes that have a chance to be selected in response to an environmental challenge (e.g. immune response, vaccine, antiviral treatment), especially in long-term infected patients.

This study has some limitations, in particular, the small number of patients included, resulting from the need for deep sequencing of each sample, which generates an enormous amount of data. In addition, tissue samples from the patients studied were not available, and it was impossible to measure intracellular ADAR-1 activity. However, the findings open the door to investigation of whether new full variants of concern may arise because of the effects of ADAR1 on the quasispecies.

In conclusion, SARS-CoV-2 quasispecies variability was higher in patients with long-lasting infection, regardless of their severity status. Deep sequencing showed that most SARS-CoV-2 mutations present in the quasispecies were of the type produced by the action of ADAR1 editing enzymes, rather than substitutions inserted by the RNA-dependent RNA
polymerase (nsp12). Furthermore, ADAR1 editing preferably occurred during replication (dsRNA with a+ and –strand), as the effects were similar on both strands. Nucleotide editing by ADAR1 took place on a small fraction of replicating genomes, but often resulted in multiple editions in the same genome, which can compromise genome fitness and replication. Further study at the long term showed very few ADAR-like mutations fixed in the GISAID consensus genomes, which is consistent with the idea that ADAR1 edition acts in the manner of a moderate antiviral by causing hypermutations that impair viral fitness. Finally, based on our data, we suggest that most, if not all, SARS-CoV-2 mutations that can be transmitted and become fixed in the consensus sequence are likely nsp12-induced and are produced in patients with high viremia and lengthy infection.

Acknowledgments

The authors thank Celine Cavallo for English language support. JG and MFC performed the ADAR1 deep data analysis, the graphic analysis and composed the figures and tables; MP, CCampos, CG-C, CA, SC-C, MCM and CCas-C conducted the experiments, performed the RNA extraction, PCR and sequencing and the RNA secondary analysis; MGC, AR, JE, ES collected patients samples, patients data, and performed patient follow up; JJ and NS helped with the theoretical analysis of data and the RNA secondary analysis; FR-F, TP and JIE revised the manuscript; AA and JQ directed the work, got the funding, analyzed the data, and wrote the manuscript with the help of JG.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Funding

This study was supported by the Direcció General de Recerca I Innovació en Salut (DGRIS) of the Catalan Health Ministry, Generalitat de Catalunya, through the Vall d’Hebron Institut de Recerca (VHIR); the European Regional Development Fund (ERDF) “A way to achieve Europe” by the Spanish Network for Research in Infectious Diseases [grant number REIPI RD16/0016/0003]; Instituto de Salud Carlos III [grant number FIS PI19/00301]; and Centro para el Desarrollo Tecnologico Industrial (CDTI) from the Ministry of Economic Affairs and Digital Transformation [grant number IDI-20200297].

ORCID

Josep Gregori http://orcid.org/0000-0002-4253-8015
Maria Francesca Cortese http://orcid.org/0000-0002-4318-532X
Maria Piñana http://orcid.org/0000-0002-4766-2613
Carolina Campos http://orcid.org/0000-0002-0132-7027
Damir García-Cehic http://orcid.org/0000-0002-0009-038X
Cristina Andrés http://orcid.org/0000-0002-3200-0895

Josep Francesc Abril http://orcid.org/0000-0001-7793-589X
Maria Gema Codina http://orcid.org/0000-0002-5313-5086
Ariadna Rando http://orcid.org/0000-0003-4555-7286
Juliana Esperalba http://orcid.org/0000-0003-1326-1341
Elena Sulleiro http://orcid.org/0000-0002-9783-6060
Joan Joseph http://orcid.org/0000-0002-4106-0208
Narcís Saubi http://orcid.org/0000-0001-5493-1044
Sergi Colomer-Castell http://orcid.org/0000-0002-0307-7455
Mari Carmen Martin http://orcid.org/0000-0003-1327-8813
Juan Ignacio Esteban http://orcid.org/0000-0001-5085-917X
Tomas Pumarola http://orcid.org/0000-0002-5171-7461
Francisco Rodriguez-Frias http://orcid.org/0000-0001-9058-4641
Andrés Antón http://orcid.org/0000-0002-1476-0815
Josep Quer http://orcid.org/0000-0003-0014-084X

References

[1] Eckerle LD, Becker MM, Halpin RA, et al. Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathog. 2010;6:e1000896.
[2] Peck KM, Lauring AS. Complexities of viral mutation rates. J Virol. 2018;92; doi:10.1128/JVI.01031-17.
[3] Rambaut A, Holmes EC, O’Toole A, et al. A dynamic nomenclature proposal for SARS-CoV-2 lineages to assist genomic epidemiology. Nat Microbiol. 2020. doi:10.1038/s41564-020-0770-5.
[4] Rowe CL, Fleming JO, Nathan MJ, et al. Generation of coronavirus spike deletion variants by high-frequency recombination at regions of predicted RNA secondary structure. J Virol. 1997;71:6183–6190.
[5] Rowe CL, Baker SC, Nathan MJ, et al. Evolution of mouse hepatitis virus: detection and characterization of spike deletion variants during persistent infection. J Virol. 1997;71:2959–2969.
[6] Muth D, Corman VM, Roth H, et al. Attenuation of replication by a 29 nucleotide deletion in SARS-coronavirus acquired during the early stages of human-to-human transmission. Sci Rep. 2018;8:15177.
[7] Lau S-Y, Wang P, Mok BW-Y, et al. Attenuated SARS-CoV-2 variants with deletions at the S1/S2 junction. Emerg Microbes Infect. 2020;9:837–842.
[8] Wong YC, Lau SY, Wang To KK, et al. Natural transmission of bat-like SARS-CoV-2 deltaPRRA variants in COVID-19 patients. Clin Infect Dis. 2020. doi:10.1093/cid/ciaa953.
[9] Young BE, Fong S-W, Chan Y-H, et al. Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and the inflammatory response: an observational cohort study. Lancet. 2020;396:603–611.
[10] Andrés C, García-Cehic D, Gregori J, et al. Naturally occurring SARS-CoV-2 gene deletions close to the spike S1/S2 cleavage site in the viral quasispecies of COVID-19 patients. Emerg Microbes Infect. 2020;9:1900–1911.
[11] Majzoub K, Wrensch F, Baumert TF. The innate antiviral response in animals: an evolutionary perspective from flagellates to humans. Viruses. 2019;11; doi:10.3390/v11080758.
[12] Cattaneo R, Schmid A, Eschle D, et al. Biased hypermutation and other genetic changes in defective measles viruses in human brain infections. Cell. 1988;55:255–265.

[13] Lehmann KA, Bass BL. The importance of internal loops within RNA substrates of ADAR1. J Mol Biol. 1999;291:1–13.

[14] Samuel CE. ADARs: viruses and innate immunity. Curr Top Microbiol Immunol. 2012;353:163–195.

[15] Piontkivska H, Matos LF, Paul S, et al. Role of host-driven mutagenesis in determining genome evolution of sigma virus (DMelSV; Rhabdoviridae) in Drosophila melanogaster. Genome Biol Evol. 2016;8:2952–2963.

[16] Phuphuakrat A, Kraiwong R, Boonarkart C, et al. Editing of HIV-1 RNA by double-stranded RNA adenosine deaminases enhances expression of human immunodeficiency virus type 1 proteins. J Virol. 2008;82:10864–10872.

[17] Tang Y-D, Na L, Fu L-H, et al. Double-stranded RNA-specific adenosine deaminase 1 (ADAR1) promotes EIAV replication and infectivity. Virology. 2015;476:364–371.

[18] Doria M, Neri F, Gallo A, et al. Editing of HIV-1 RNA by the double-stranded RNA deaminase ADAR1 stimulates viral infection. Nucleic Acids Res. 2009;37:5848–5858.

[19] Casey JL. Control of ADAR1 editing of hepatitis delta virus RNAs. Curr Top Microbiol Immunol. 2012;353:123–143.

[20] Clerzius G, Gélinas J-F, Gatignol A. Multiple levels of PKR inhibition during HIV-1 replication. Rev Med Virol. 2011;21:42–53.

[21] Wong SK, Lazinski DW. Replicating hepatitis delta virus RNA is edited in the nucleus by the small form double-stranded RNA deaminase acting on double-stranded RNA. Proc Natl Acad Sci U S A. 2002;99:15118–15123.

[22] Rangan R, Zheleudev IN, Das R. RNA genome conservation and secondary structure in SARS-CoV-2 and SARS-related viruses, bioRxiv Prepr Serv Biol. 2020. doi:10.1101/2020.03.27.012906.

[23] Di Giorgio S, Martignano F, Torcia MG, et al. Evidence for host-dependent RNA editing in the transcriptome of SARS-CoV-2. Sci Adv. 2020;6:eabb5813.

[24] Chen Q, Perales C, Soria ME, et al. Deep-sequencing reveals broad subtype-specific HCV resistance mutations associated with treatment failure. Antiviral Res. 2020;174. doi:10.1016/j.antiviral.2019.104694.

[25] Perales C, Chen Q, Soria ME, et al. Baseline hepatitis C virus resistance-associated substitutions present at frequencies lower than 15% may be clinically significant. Infect Drug Resist. 2018;11:2207–2210.

[26] Magoc T, Salzberg SL. FLASH: fast length adjustment of short reads to improve genome assemblies. Bioinformatics. 2011;27:2957–2963.

[27] Gregori J, Salicru M, Domingo E, et al. Inference with viral quasispecies diversity indices: clonal and NGS approaches. Bioinformatics. 2014;30; doi:10.1093/bioinformatics/btt768.

[28] R Core Team. R: a language and environment for statistical computing. Vienna, Austria: R Foundation for Statistical Computing; 2020.

[29] Pages H, Aboyoun P, Gentleman R, et al. Biostrings: string objects representing biological sequences, and matching algorithms. R package 2.38.4. 2012.

[30] Paradis E, Schliep K. ape 5.0: an environment for modern phylogenetics and evolutionary analyses in R. Bioinformatics. 2019;35:526–528.

[31] Morgan M, Anders S, Lawrence M, et al. Shortread: a bioconductor package for input, quality assessment and exploration of high-throughput sequence data. Bioinformatics. 2009;25:2607–2608.

[32] Wagh O. Gqseqlogo: a versatile R package for drawing sequence logos. Bioinformatics. 2017;33:3645–3647.

[33] Gallego I, Gregori J, Soria ME, et al. Resistance of high fitness hepatitis C virus to lethal mutagenesis. Virology. 2018;523:100–109.

[34] Gregori J, Perales C, Rodriguez-Frias F, et al. Viral quasispecies complexity measures. Virology. 2016;493. doi:10.1016/j.virol.2016.03.017.

[35] Gregori J, Soria ME, Gallego I, et al. Rare haplotype load as marker for lethal mutagenesis. PLoS One. 2018;13:e0204877.

[36] Lehmann KA, Bass BL. Double-stranded RNA adenosine deaminases ADAR1 and ADAR2 have overlapping specificities. Biochemistry. 2000;39:12875–12884.

[37] Zuker M, Stiegler P. Optimal computer folding of large RNA sequences using thermodynamics and auxiliary information. Nucleic Acids Res. 1981;9:133–148.

[38] Gruber AR, Lorenz R, Bernhart SH, et al. The Vienna RNA web suite. Nucleic Acids Res. 2008;36:W70–W74.

[39] Lorenz R, Bernhart SH, Höner Zu Siederdissen C, et al. Vienna RNA package 2.0. Algorith Mol Biol. 2011;6:26.

[40] Mercatelli D, Giorgi FM. Geographic and genomic distribution of SARS-CoV-2 mutations. Front Microbiol. 2020;11:1800.

[41] Smith EC, Denison MR. Coronaviruses as DNA wannabes: a new model for the regulation of RNA virus replication fidelity. PLoS Pathog. 2013;9:e1003760.

[42] Gribble J, Prijoulsers AJ, Agostini ML, et al. The coronavirus proofreading exoribonuclease mediates extensive viral recombination. bioRxiv. 2020. doi:10.1101/2020.04.23.057786.

[43] Tomaselli S, Galeano F, Locatelli F, et al. ADARs and the balance game between virus infection and innate immune cell response. Curr Issues Mol Biol. 2015;17:37–51.

[44] van Dorp L, Acman M, Richard D, et al. Emergence of genomic diversity and recurrent mutations in SARS-CoV-2. Infect Genet Evol J Mol Epidemiol Evol Genet Dis. 2020;83:104351.

[45] Shu Y, McCauley J. GISAID: global initiative on sharing all influenza data – from vision to reality. Euro Surveill Bull Eur sur les Mal Transm Eur Commun Dis Bull. 2017;22. doi:10.2807/1560-7917.ES.2017.22.13.30494.

[46] Elbe S, Buckland-Merrett G. Data, disease and diplomacy: GISAID’s innovative contribution to global health. Glob Challen. 2017;1:33–46.

[47] García-Crespo C, Soria ME, Gallego I, et al. Dissimilar conservation pattern in hepatitis C virus mutant spectra, consensus sequences, and data banks. J Clin Med. 2020;9. doi:10.3390/jcm9113450.

[48] Novella IS, Quer J, Domingo E, et al. Exponential viral recombination in the transcriptome of SARS-CoV-2. Sci Adv. 2020;6:eabc5813.

[49] Yang Y, Chen T, Mui D, et al. Cardiovascular manifestations and treatment considerations in COVID-19. Heart. 2020;106:1132–1141.

[50] Mapping the human genetic architecture of COVID-19. Nature. 2021. doi:10.1038/s41586-021-03767-x.
[53] Martinez MA, Vartanian JP, Wain-Hobson S. Hypermutagenesis of RNA using human immunodeficiency virus type 1 reverse transcriptase and biased dNTP concentrations. Proc Natl Acad Sci USA. 1994;91:11787–11791.

[54] Martinez MA, Sala M, Vartanian JP, et al. Reverse transcriptase and substrate dependence of the RNA hypermutagenesis reaction. Nucleic Acids Res. 1995;23:2573–2578.

[55] Carpenter JA, Keegan LP, Wilfert L, et al. Evidence for ADAR-induced hypermutation of the Drosophila sigma virus (Rhabdoviridae). BMC Genet. 2009;10:75.

[56] Vandelli A, Monti M, Milanetti E, et al. Structural analysis of SARS-CoV-2 genome and predictions of the human interactome. Nucleic Acids Res. 2020;48:11270–11283.